Zhejiang Peptites Biotech Co.,Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Zhejiang Peptites Biotech Co.,Ltd.?

Yes. FDA’s import refusal records list 6 refused shipment lines declared as made by Zhejiang Peptites Biotech Co.,Ltd. (China) whose FDA product code names tirzepatide and semaglutide, from Aug 30, 2023 to Mar 15, 2024. 4 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Shaoxing
FEI numbers on the lines
3015685285
Refused lines
6
Lines with an Import Alert 66-80 API or powder code
4
Drugs named in the product codes
Tirzepatide, Semaglutide
Refusal dates
Aug 30, 2023 to Mar 15, 2024

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Zhejiang Peptites Biotech Co.,Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Mar 15, 2024China61PDY74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-9672874-7/11/1
Oct 11, 2023China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.906-0395480-4/11/1
Sep 27, 2023China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8V8-0000195-1/11/2
Sep 7, 2023China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8GX-8000731-3/11/1
Aug 30, 2023China61PCK72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).390-9824420-3/11/1A
Aug 30, 2023China61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
390-9824420-3/11/1B

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.3
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).2
UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).2

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 3 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Zhejiang Peptites Biotech Co., Ltd.” and “Zhejiang Peptites Biotech Co., Ltd”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (3).

73569-051Zhejiang Peptites Biotech Co., Ltd.Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGDec 6, 2024None givenDec 31, 2027Unfinished drugs
73569-035Zhejiang Peptites Biotech Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 26, 2022None givenDec 31, 2027Unfinished drugs
73569-050Zhejiang Peptites Biotech Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGDec 29, 2023None givenDec 31, 2027Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

6 lines from FDA files read Nov 15, 2026.